TY - JOUR
T1 - Eltrombopag-induced Cortical Vein Thrombosis
T2 - A Case Report
AU - Selvarajan, Tarun
AU - Acharya, Vasudeva
AU - Sukumar, Cynthia Amrutha
AU - Nandakrishna, B.
AU - Kamath, Nagraj
AU - Balasubramanian, Rukmoni
N1 - Publisher Copyright:
© 2023, Indian Academy of Clinical Medicine. All rights reserved.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Eltrombopag, a thrombopoietin receptor agonist is widely used in the treatment of immune thrombocytopenic purpura (ITP), aplastic anaemia and post-transplant cytopenia. Eltrombopag is used as second-line treatment in ITP. We describe a rare and life-threatening complication of this drug namely cortical venous thrombosis in a patient with ITP. Pathogenetic mechanisms behind the thrombosis may vary from case to case. Thrombosis may be linked to the platelet count or additional thrombophilic states. Regular monitoring of patients on therapy with Eltrombopag is required to avoid these complications.
AB - Eltrombopag, a thrombopoietin receptor agonist is widely used in the treatment of immune thrombocytopenic purpura (ITP), aplastic anaemia and post-transplant cytopenia. Eltrombopag is used as second-line treatment in ITP. We describe a rare and life-threatening complication of this drug namely cortical venous thrombosis in a patient with ITP. Pathogenetic mechanisms behind the thrombosis may vary from case to case. Thrombosis may be linked to the platelet count or additional thrombophilic states. Regular monitoring of patients on therapy with Eltrombopag is required to avoid these complications.
UR - https://www.scopus.com/pages/publications/85185528584
UR - https://www.scopus.com/pages/publications/85185528584#tab=citedBy
M3 - Article
AN - SCOPUS:85185528584
SN - 0972-3560
VL - 24
SP - 221
EP - 223
JO - Journal, Indian Academy of Clinical Medicine
JF - Journal, Indian Academy of Clinical Medicine
IS - 3-4
ER -